Clustering of HR + /HER2-breast cancer in an Asian cohort is driven by immune phenotypes

• Main Authors: Pan, Jia-Wern, Ragu, Mohana, Chan, Wei-Qin, Hasan, Siti Norhidayu, Islam, Tania, Teoh, Li-Ying, Jamaris, Suniza, See, Mee-Hoong, Yip, Cheng-Har, Rajadurai, Pathmanathan, Looi, Lai Meng, Taib, Nur Aishah Mohd, Rueda, Oscar M., Caldas, Carlos, Chin, Suet-Feung, Lim, Joanna, Teo, Soo Hwang
• Format: Article
• Published: BMC 2024
• Subjects: R Medicine
• Online Access: http://eprints.um.edu.my/45297/; https://doi.org/10.1186/s13058-024-01826-5
• Institution: Universiti Malaya

Breast cancer exhibits significant heterogeneity, manifesting in various subtypes that are critical in guiding treatment decisions. This study aimed to investigate the existence of distinct subtypes of breast cancer within the Asian population, by analysing the transcriptomic profiles of 934 breast cancer patients from a Malaysian cohort. Our findings reveal that the HR + /HER2- breast cancer samples display a distinct clustering pattern based on immune phenotypes, rather than conforming to the conventional luminal A-luminal B paradigm previously reported in breast cancers from women of European descent. This suggests that the activation of the immune system may play a more important role in Asian HR + /HER2- breast cancer than has been previously recognized. Analysis of somatic mutations by whole exome sequencing showed that counter-intuitively, the cluster of HR + /HER2- samples exhibiting higher immune scores was associated with lower tumour mutational burden, lower homologous recombination deficiency scores, and fewer copy number aberrations, implicating the involvement of non-canonical tumour immune pathways. Further investigations are warranted to determine the underlying mechanisms of these pathways, with the potential to develop innovative immunotherapeutic approaches tailored to this specific patient population.